2.2. Interventions
The patients were allocated randomly into two groups using 60 sequentially numbered, opaque, sealed envelopes that had been prepared earlier using a computerized table of random numbers (using RSudio), and which were balanced to ensure equal numbers in each group. The allocations were concealed from the statistician until the statistical analysis had been completed. Significant heterogeneity exists amongst the studies regarding time of treatment initiation, treatment dosage, and duration. In our study, the dosage of Cerebrolysin was based on previously published data from a meta-analysis of nine randomized trials evaluating Cerebrolysin’s clinical efficacy compared to a placebo. Treatment efficacy was demonstrated primarily with daily 30 mL Cerebrolysin infusions for 10 or 21 days when initiated within 12 to 72 h of symptom onset [